Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Miscellaneous

This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of DCC-2618 to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to DCC-2618 150 mg once daily (QD) (continuous dosing for 6 week cycles) or sunitinib 50 mg QD (6 week cycles, 4 weeks on, 2 weeks off).
Miscellaneous
III
Keedy, Vicki
NCT03673501
VICCSAR18147

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: